The Biosimilar Gold Rush Begins

May 2026 — The global pharmaceutical industry is witnessing an unprecedented wave of biosimilar acquisitions and strategic partnerships as companies position themselves for what industry analysts call the "golden decade" of blockbuster biologic patent expirations. With an estimated $300 billion in biologic drug sales facing patent cliffs over the next ten years, the race to secure biosimilar development, manufacturing, and commercial capabilities has intensified dramatically.

India's Sun Pharmaceutical Industries announced the acquisition of U.S.-based Organon for $11.75 billion, marking the largest deal in Indian pharmaceutical history. Organon, spun off from Merck & Co. in 2021, sells biosimilars and other pharmaceuticals in 140 countries. Simultaneously, U.S. generics company Amneal Pharmaceuticals acquired biosimilar firm Kashiv BioSciences for $1.1 billion, securing four manufacturing facilities across the U.S. and India.

Sandoz-Samsung Bioepis: A New Partnership Model

Switzerland-based Sandoz, the world's largest generics and biosimilars company, has expanded its partnership with Samsung Bioepis through a global development and commercialization agreement covering up to five biosimilar candidates. The first asset, SB36, is a biosimilar of Takeda's Entyvio (vedolizumab), a treatment for inflammatory bowel disease generating approximately $5 billion in annual global sales.

Under the agreement, Samsung Bioepis handles development and manufacturing while Sandoz gains exclusive global commercialization rights outside Greater China and South Korea. This partnership builds on the companies' successful 2023 collaboration for Pyzchiva (ustekinumab biosimilar). Sandoz has also announced plans to establish a standalone biosimilar unit, separating its biologics business from its small molecule generics division to accelerate decision-making and vertical integration.

Market Drivers: The $110 Billion Opportunity

The U.S. biosimilar market is projected to grow from $23 billion in 2025 to $110 billion by 2035, driven by several converging factors:

• Patent expirations: Blockbuster biologics including Stelara, Entyvio, Keytruda, and others face patent cliffs in the coming years
• Regulatory streamlining: The FDA's abbreviated biosimilar approval pathway has reduced development time by approximately two years and costs by 50%
• Payer pressure: Growing healthcare costs drive demand for lower-priced biosimilar alternatives
• IRA impact: The Inflation Reduction Act's Medicare drug pricing negotiations accelerate biosimilar adoption

Implications for API and CDMO Suppliers

The biosimilar expansion creates substantial demand across the pharmaceutical manufacturing supply chain:

• Biologics manufacturing capacity: As more biosimilars advance through clinical trials and approach commercialization, demand for GMP-grade biologics manufacturing capacity — including mammalian cell culture, microbial fermentation, and fill-finish services — will intensify significantly.
• Raw material supply: Biosimilar production requires specialized inputs including cell culture media, chromatography resins (Protein A, ion exchange), viral filtration membranes, and single-use bioprocessing technologies.
• Formulation and fill-finish: Prefilled syringe components, autoinjector devices, and cold-chain packaging solutions are critical for biosimilar commercialization, particularly for subcutaneous formulations.
• Analytical services: Biosimilar development requires extensive comparability studies, including physicochemical characterization, biological activity assays, and immunogenicity testing.

Competitive Dynamics: Traditional Generics vs. Biosimilar Specialists

The entry of traditional generics companies into the biosimilar space is reshaping competitive dynamics. Companies like Sun Pharma, Amneal, and Sandoz are leveraging their existing manufacturing infrastructure, distribution networks, and regulatory expertise to challenge established biosimilar specialists including Samsung Bioepis and Celltrion.

Korean industry analysts note that this wave of acquisitions reflects a race for economies of scale and market preemption. The combination of streamlined FDA clinical trial requirements and looming patent expirations creates a narrow window for companies to establish market positions before competition intensifies.

Strategic Recommendations for Suppliers

B2B pharmaceutical suppliers should consider the following strategic actions:

• Scale biologics capabilities: Invest in GMP manufacturing capacity, particularly for mammalian cell culture and downstream purification, to meet growing biosimilar production demand.
• Diversify client base: The expansion of biosimilar developers beyond traditional biotech companies creates new customer segments. Established generics companies entering biosimilar markets may seek outsourcing partners for specialized capabilities.
• Develop biosimilar-specific services: Offer integrated comparability study packages, regulatory dossier support, and analytical method development tailored to biosimilar development requirements.
• Build geographic reach: As biosimilar commercialization expands globally, suppliers with multi-regional manufacturing and distribution capabilities will be better positioned to serve multinational biosimilar developers.

Outlook

The current wave of biosimilar acquisitions signals the beginning of a structural shift in the pharmaceutical industry. As patent cliffs approach and regulatory pathways mature, the biosimilar market is poised for sustained growth. For API and CDMO suppliers, the opportunity extends beyond direct manufacturing to encompass the entire value chain from cell line development through commercial fill-finish. Companies that establish scalable, high-quality biologics manufacturing capabilities now will be well-positioned to capture a share of the estimated $110 billion U.S. biosimilar market by 2035.